Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Duopharma Biotech Berhad (7148.KL)
Kuala Lumpur, MY
Duopharma Biotech Berhad, an investment holding firm, is actively engaged in the pharmaceutical sector. Its operations encompass the research, development, manufacturing, distribution, and import of medicinal products, serving markets in Malaysia and internationally. The company's extensive product range includes consumer health items like vitamins, nutritional supplements, pain relievers, eye care solutions, antacids, and skincare products. It also provides generic medications across various therapeutic classes, such as cardiovascular, dermatological, hormonal, respiratory, neurological, musculoskeletal, and anti-infective agents. Furthermore, Duopharma offers specialized pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables, addressing ailments like diabetes, cancer, cardiovascular diseases, and renal disorders. Notable products include vascor, insugen, kytron, and unihepa. Its well-known brands feature Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol. Beyond its core pharmaceutical activities, the company is also involved in property management and the trading of chemical products. Founded in 1978 and headquartered in Kuala Lumpur, Malaysia, the company adopted its current name, Duopharma Biotech Berhad, in February 2019, having previously been known as CCM Duopharma Biotech Berhad.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00% | -0.76% | +0.78% | -16.13% | +0.78% | +4.00% | +1.56% | -10.34% | -39.25% | +75.84% | +89.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+14.5% ★ Q1'26: -5.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+39.6% ★ Q1'26: +19.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.3% Q1'26: +8.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.6% ★ Q1'26: +18.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.8% ★ Q1'26: +14.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.80× Q1'26: 2.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
312.94M
est: 321.10M (-2.5%)
|
467.99M
est: 453.80M (+3.1%)
|
498.72M
est: 514.90M (-3.1%)
|
576.46M
est: 574.50M (+0.3%)
|
569.90M
est: 630.37M (-9.6%)
|
639.18M
est: 654.57M (-2.4%)
|
696.72M
est: 734.53M (-5.1%)
|
704.73M
est: 668.93M (+5.4%)
|
813.70M
est: 800.53M (+1.6%)
|
931.69M
est: 926.96M (+0.5%)
|
1.01B
935.00M – 1.15B
+8.7% YoY
|
1.06B
988.40M – 1.19B
+4.7% YoY
|
1.06B
991.29M – 1.21B
+0.8% YoY
|
| EBITDA |
59.53M
est: 60.18M (-1.1%)
|
81.16M
est: 85.05M (-4.6%)
|
92.12M
est: 96.50M (-4.5%)
|
105.96M
est: 107.67M (-1.6%)
|
111.75M
est: 118.14M (-5.4%)
|
121.91M
est: 122.67M (-0.6%)
|
130.63M
est: 137.66M (-5.1%)
|
124.00M
est: 125.37M (-1.1%)
|
152.01M
est: 148.92M (+2.1%)
|
176.25M
est: 172.44M (+2.2%)
|
187.50M
173.94M – 214.33M
+8.7% YoY
|
196.31M
183.87M – 221.32M
+4.7% YoY
|
197.81M
184.41M – 224.53M
+0.8% YoY
|
| EBIT |
36.82M
est: 42.85M (-14.1%)
|
56.77M
est: 60.56M (-6.3%)
|
67.22M
est: 68.71M (-2.2%)
|
78.77M
est: 76.67M (+2.7%)
|
82.68M
est: 84.12M (-1.7%)
|
89.42M
est: 87.35M (+2.4%)
|
93.95M
est: 98.02M (-4.2%)
|
81.46M
est: 89.27M (-8.7%)
|
106.62M
est: 106.90M (-0.3%)
|
135.56M
est: 123.78M (+9.5%)
|
134.59M
124.85M – 153.84M
+8.7% YoY
|
140.91M
131.98M – 158.86M
+4.7% YoY
|
141.99M
132.37M – 161.16M
+0.8% YoY
|
| Net Income |
26.83M
est: 27.83M (-3.6%)
|
42.46M
est: 43.29M (-1.9%)
|
47.64M
est: 51.58M (-7.6%)
|
55.27M
est: 62.33M (-11.3%)
|
58.61M
est: 63.01M (-7.0%)
|
65.68M
est: 70.86M (-7.3%)
|
70.11M
est: 91.14M (-23.1%)
|
52.65M
est: 67.82M (-22.4%)
|
62.65M
est: 65.41M (-4.2%)
|
87.46M
est: 91.62M (-4.5%)
|
101.77M
95.47M – 109.80M
+11.1% YoY
|
109.28M
105.26M – 115.78M
+7.4% YoY
|
113.51M
103.51M – 133.44M
+3.9% YoY
|
| SGA |
109.30M
est: 83.76M (+30.5%)
|
128.67M
est: 118.38M (+8.7%)
|
137.83M
est: 134.32M (+2.6%)
|
155.35M
est: 149.87M (+3.7%)
|
150.81M
est: 164.44M (-8.3%)
|
165.78M
est: 170.75M (-2.9%)
|
186.59M
est: 191.61M (-2.6%)
|
187.46M
est: 174.50M (+7.4%)
|
200.58M
est: 205.57M (-2.4%)
|
227.58M
est: 238.03M (-4.4%)
|
258.82M
240.10M – 295.85M
+8.7% YoY
|
270.97M
253.81M – 305.50M
+4.7% YoY
|
273.05M
254.55M – 309.93M
+0.8% YoY
|
| EPS |
0.03
est: 0.03 (+6.8%)
|
0.05
est: 0.05 (+8.7%)
|
0.05
est: 0.05 (+1.6%)
|
0.06
est: 0.06 (-4.6%)
|
0.06
est: 0.07 (-3.1%)
|
0.07
est: 0.07 (-4.0%)
|
0.07
est: 0.09 (-22.0%)
|
0.05
est: 0.07 (-22.1%)
|
0.07
est: 0.07 (-4.3%)
|
0.09
est: 0.10 (-4.6%)
|
0.11
0.10 – 0.11
+11.1% YoY
|
0.11
0.11 – 0.12
+7.4% YoY
|
0.12
0.11 – 0.14
+3.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 129.2K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 62.4K | 0.28% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 310.33 | 0.56% |
| 4 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 3.2K | 0.33% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 167.63 | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ibrahim Hussin Salleh | Chief Legal Officer & Group Company Secretary | — | male |
| Krisnakumara Reddi | Chief Manufacturing & Sustainability Officer | — | male |
| Noor Aida Binti Jaafar | Chief Commercial Officer | — | female |
| Priya Darshini | Chief Innovation Officer | — | female |
| Rohayu Rosnani Binti Mohd Adanan | Chief Financial Officer | — | female |
| Sabrina Binti Haron | Chief Compliance Officer | — | female |
| Shamsul Idham Bin A. Iahad | Chief Consumer Healthcare Officer | — | male |
| Wan Ahmad Nizam Bin Wan Mohd. Salleh | Group Head of Risk Management & Integrity | — | male |
| Wan Amir-Jeffery Bin Wan Abdul Majid | CEO & Principal Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7148.KL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
